Amicus Therapeutics, Inc. (FOLD): Price and Financial Metrics

Amicus Therapeutics, Inc. (FOLD): $9.80

-0.07 (-0.71%)

POWR Rating

Component Grades













Add FOLD to Watchlist
Sign Up

Industry: Biotech


of 491

in industry

FOLD Stock Summary

  • Of note is the ratio of Amicus Therapeutics Inc's sales and general administrative expense to its total operating expenses; only 17.76% of US stocks have a lower such ratio.
  • With a year-over-year growth in debt of 110.12%, Amicus Therapeutics Inc's debt growth rate surpasses 90.38% of about US stocks.
  • As for revenue growth, note that FOLD's revenue has grown 43.16% over the past 12 months; that beats the revenue growth of 88.46% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Amicus Therapeutics Inc, a group of peers worth examining would be RGLS, STRO, LOGC, MRUS, and DCPH.
  • FOLD's SEC filings can be seen here. And to visit Amicus Therapeutics Inc's official web site, go to

FOLD Stock Price Chart Interactive Chart >

Price chart for FOLD

FOLD Price/Volume Stats

Current price $9.80 52-week high $25.39
Prev. close $9.87 52-week low $8.83
Day low $9.79 Volume 628,354
Day high $10.01 Avg. volume 3,883,104
50-day MA $10.64 Dividend yield N/A
200-day MA $16.31 Market Cap 2.59B

Amicus Therapeutics, Inc. (FOLD) Company Bio

Amicus Therapeutics is developing treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage disorders. The company was founded in 2002 and is based in Cranbury, New Jersey.

FOLD Latest News Stream

Event/Time News Detail
Loading, please wait...

FOLD Latest Social Stream

Loading social stream, please wait...

View Full FOLD Social Stream

Latest FOLD News From Around the Web

Below are the latest news stories about Amicus Therapeutics Inc that investors may wish to consider to help them evaluate FOLD as an investment opportunity.

Amicus Therapeutics (FOLD) Investor Presentation - Slideshow

The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | April 15, 2021

Fold gets back overweight rating from Cantor; says Pompe disease candidate given ‘zero credit’

Amicus Therapeutics ([[FOLD]] +8.4%) is sharply higher today after Cantor Fitzgerald upgraded the stock to overweight from neutral with the unchanged price target at $17.00 per share implying ~82.6% upside to the previous close.The company has lost ~51% since it announced the Phase 3 top-line data for the two-component experimental...

Seeking Alpha | April 14, 2021

Why Amicus Therapeutics Stock Is Soaring Today

Shares of Amicus Therapeutics (NASDAQ: FOLD) were soaring 9.7% higher at 12:07 p.m. EDT on Wednesday. The big gain came after Cantor Fitzgerald analyst Kristen Kluska upgraded Amicus stock to overweight from neutral. In this case, Cantor Fitzgerald's Kluska likes the prospects for Amicus because she thinks the company's gene therapy candidates are promising based on recent clinical updates.

Yahoo | April 14, 2021

Is FOLD Stock A Buy or Sell?

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out […]

Yahoo | April 8, 2021

Amicus Therapeutics Announces Presentation and Posters at the 2021 MDA Clinical & Scientific Conference

PHILADELPHIA, March 15, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced one oral presentation and two posters highlighting its development program for Pompe disease will be included at the 2021 MDA Virtual Clinical & Scientific Conference to be held March 15-18, 2021. Oral Platform Presentation: Thursday, March 18, 5:30 – 5:45 p.m. ET Efficacy and safety of AT-GAA (cipaglucosidase alfa/miglustat) versus alglucosidase alfa/placebo in late-onset Pompe disease (LOPD): A phase 3 trial (PROPEL) Presenter: Tahseen Mozaffar, MD, FAAN, University of California, Irvine, CA, USA Poster Presentations: Characterization of Response to Enzyme Replacement Therapy in Patients With Late-Onset Pompe Disease: A Retrospective Chart Review Presenter: Priya Kishnani, MD, MBBS, Du...

Yahoo | March 15, 2021

Read More 'FOLD' Stories Here

FOLD Price Returns

1-mo 4.48%
3-mo -53.53%
6-mo -46.97%
1-year -18.87%
3-year -28.93%
5-year 21.74%
YTD -57.56%
2020 137.06%
2019 1.67%
2018 -33.43%
2017 189.54%
2016 -48.76%

Continue Researching FOLD

Here are a few links from around the web to help you further your research on Amicus Therapeutics Inc's stock as an investment opportunity:

Amicus Therapeutics Inc (FOLD) Stock Price | Nasdaq
Amicus Therapeutics Inc (FOLD) Stock Quote, History and News - Yahoo Finance
Amicus Therapeutics Inc (FOLD) Stock Price and Basic Information | MarketWatch

Page generated in 1.4341 seconds.